SKIV2L2 DOWN in 'camptothecin' vs 'none'
PAFAH1B1 DOWN in 'camptothecin' vs 'none'
TRAPPC8 DOWN in 'camptothecin' vs 'none'
OSBPL10 DOWN in 'camptothecin' vs 'none'
ERBB2IP DOWN in 'camptothecin' vs 'none'
IGF2BP3 DOWN in 'camptothecin' vs 'none'
(Assay) Camptothecin Treated HeLa Replicate 2 U133A
Camptothecin Treated HeLa Replicate 2 U133A
SLCO3A1 DOWN in 'camptothecin' vs 'none'
(Assay) Camptothecin Treated HeLa Replicate 3 U133A
Camptothecin Treated HeLa Replicate 3 U133A
DENND1B DOWN in 'camptothecin' vs 'none'
RPS6KC1 DOWN in 'camptothecin' vs 'none'
CAMSAP2 DOWN in 'camptothecin' vs 'none'
(Assay) Untreated HeLa Replicate 2 U133A
PLEKHA5 DOWN in 'camptothecin' vs 'none'
RAD51AP1 DOWN in 'camptothecin' vs 'none'
CAMSAP1 DOWN in 'camptothecin' vs 'none'
SLC7A11 DOWN in 'camptothecin' vs 'none'
KIAA1033 DOWN in 'camptothecin' vs 'none'
LRRFIP2 DOWN in 'camptothecin' vs 'none'
PPP1R12A DOWN in 'camptothecin' vs 'none'
CSGALNACT1 DOWN in 'camptothecin' vs 'none'
ZDHHC17 DOWN in 'camptothecin' vs 'none'
RPS6KA2 DOWN in 'camptothecin' vs 'none'
HNRNPDL DOWN in 'camptothecin' vs 'none'
RABGAP1 DOWN in 'camptothecin' vs 'none'
(Assay) Untreated HeLa Replicate 4 U133A
SIPA1L1 DOWN in 'camptothecin' vs 'none'
CTC-338M12.4 UP in 'camptothecin' vs 'none'
LINC00963 DOWN in 'camptothecin' vs 'none'
SYNCRIP DOWN in 'camptothecin' vs 'none'
ARHGDIA DOWN in 'camptothecin' vs 'none'
PPP2R5C DOWN in 'camptothecin' vs 'none'
GTF2IRD1 DOWN in 'camptothecin' vs 'none'
PIK3C2A DOWN in 'camptothecin' vs 'none'
Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. The response of tumor cells to the unusual form of DNA damage caused by topoisomerase poisons such as camptothecin (CPT) is poorly understood, and knowledge regarding which drugs can be effectively combined with CPT is lacking. To better understand the response of tumor cells to CPT and to identify potential targets for adjuvant therapy, we examined global changes in mRNA abundance in HeLa cells after CPT treatment using Affymetrix U133A GeneChips, which include all annotated human genes (22,283 probe sets). Statistical analysis of the data using a Bayesian/Cyber t test and a modified Benjamini and Hochberg correction for multiple hypotheses testing identified 188 probe sets that are induced and 495 that are repressed 8 h after CPT treatment at a False Discovery Rate of <0.05 and a minimum 3-fold change. This pharmacogenomic approach led us to identify two pathways that are CPT induced: (a) the epidermal growth factor receptor; and (b) nuclear factor-kappaB-regulated antiapoptotic factors. Experiments using HeLa cells in our lab and prior animal model studies performed elsewhere confirm that inhibitors of these respective pathways super-additively enhance CPT's cytotoxicity, suggesting their potential as targets for adjuvant therapy with CPT. Cancer Res. 2004 Mar 15;64(6):2096-104
RAPGEF2 DOWN in 'camptothecin' vs 'none'
ZCCHC14 DOWN in 'camptothecin' vs 'none'
RHOBTB3 DOWN in 'camptothecin' vs 'none'
DENND5A DOWN in 'camptothecin' vs 'none'
FAM208A DOWN in 'camptothecin' vs 'none'
SLC25A12 DOWN in 'camptothecin' vs 'none'
TMEM168 DOWN in 'camptothecin' vs 'none'
ARFGEF1 DOWN in 'camptothecin' vs 'none'
ARHGEF10 DOWN in 'camptothecin' vs 'none'
HDGFRP3 DOWN in 'camptothecin' vs 'none'
CCDC90B DOWN in 'camptothecin' vs 'none'
SLC38A1 DOWN in 'camptothecin' vs 'none'
ARFGEF2 DOWN in 'camptothecin' vs 'none'
HIST2H2BE UP in 'camptothecin' vs 'none'
CREB3L2 DOWN in 'camptothecin' vs 'none'
SLC25A32 DOWN in 'camptothecin' vs 'none'
(Assay) Untreated HeLa Replicate 1 U133A
ANKRD11 DOWN in 'camptothecin' vs 'none'
TRMT61B DOWN in 'camptothecin' vs 'none'
LDLRAD4 DOWN in 'camptothecin' vs 'none'
SLC16A7 DOWN in 'camptothecin' vs 'none'
FAM208B DOWN in 'camptothecin' vs 'none'
TUBGCP3 DOWN in 'camptothecin' vs 'none'
(Assay) Camptothecin Treated HeLa Replicate 1 U133A
Camptothecin Treated HeLa Replicate 1 U133A
RP11-553L6.5 DOWN in 'camptothecin' vs 'none'
ANKRD27 DOWN in 'camptothecin' vs 'none'
RAB3GAP2 DOWN in 'camptothecin' vs 'none'
(Assay) Untreated HeLa Replicate 3 U133A
SEC23IP DOWN in 'camptothecin' vs 'none'
PACSIN2 DOWN in 'camptothecin' vs 'none'
ANKRD17 DOWN in 'camptothecin' vs 'none'
RPS6KA3 DOWN in 'camptothecin' vs 'none'
TMEM135 DOWN in 'camptothecin' vs 'none'
RALGAPA1 DOWN in 'camptothecin' vs 'none'
MAPKAPK5-AS1 UP in 'camptothecin' vs 'none'
ZFYVE16 DOWN in 'camptothecin' vs 'none'
NSMCE4A DOWN in 'camptothecin' vs 'none'